BioMedNewsBreaks

MondayDec 16, 2024 11:01 am

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary

Scinai Immunotherapeutics (NASDAQ: SCNI) has established a U.S.-based subsidiary, Scinai Bioservices Inc., to enhance its Contract Development and Manufacturing Organization (CDMO) operations and address the growing demand for early-stage biologics development in the U.S. Operating from a cGMP-compliant facility in Jerusalem, Israel, Scinai Bioservices has supported nine biotech companies since its 2024 launch and recently signed its first U.S. customer, Serpin Pharma. The new subsidiary will provide boutique CDMO services tailored to early-stage biotech startups, leveraging U.S. grant funding opportunities while addressing concerns related to the BIOSECURE Act. Scinai anticipates significant growth in its CDMO revenues and reputation in the…

Continue Reading

MondayDec 16, 2024 9:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures FDA Clearance for Innovative Arrhythmia Assessment Device

HeartBeam (NASDAQ: BEAT) has received FDA 510(k) clearance for its groundbreaking HeartBeam system, a credit card-sized, cable-free ECG device designed for comprehensive arrhythmia assessment. The system enables patients to record high-fidelity heart signals from three directions during symptoms, with data transmitted to physicians for timely review and action. This milestone marks the first FDA-cleared device of its kind and lays the foundation for future advancements, including synthesized 12-lead ECGs, AI-driven arrhythmia detection, and heart attack risk assessment. HeartBeam aims to transform cardiac care by delivering actionable insights and predictive diagnostics for patients and physicians globally. To view the full press…

Continue Reading

FridayDec 13, 2024 3:08 pm

BioMedNewsBreaks — Jackson Acquisition Company II (NYSE: JACS.U) Announces Closing of IPO

Jackson Acquisition Company (NYSE: JACS.U) has closed its initial public offering of 23,000,000 units at $10.00 per unit. According to the announcement, the offering size reflects the full exercise of the underwriter’s over-allotment option. The units began trading on the New York Stock Exchange under the ticker symbol JACS.U on Dec. 10, 2024. Each unit consists of one Class A ordinary share and one right to receive one-tenth (1/10) of a Class A ordinary share upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are…

Continue Reading

ThursdayDec 12, 2024 1:47 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) at the Forefront of Cancer Treatment Innovation

Calidi Biotherapeutics (NYSE American: CLDI) was featured in a recent article that showcased the company as a compelling example of progress of emerging therapies and advances that are reshaping the fight against cancer. Calidi’s “recent data on its RTNova(TM) systemic enveloped virotherapy technology demonstrates the potential of cutting-edge solutions to revolutionize cancer care,” the article reads. “At two major conferences—the International Oncolytic Virotherapy Conference (‘IOVC’) and the Society for Immunotherapy of Cancer (‘SITC’) Annual Meeting—Calidi presented groundbreaking data supporting the capabilities of its proprietary RTNova systemic enveloped virotherapy platform. RTNova is designed to address the limitations of traditional virotherapy by offering…

Continue Reading

ThursdayDec 12, 2024 12:04 pm

BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Secures $1M Premium Equity Funding to Advance Age-Reversal Therapies

Telomir Pharmaceuticals (NASDAQ: TELO) has raised $1 million in equity funding from The Starwood Trust through a common stock transaction priced at $7 per share, a 20% premium to the closing price. This follows an undrawn $5 million non-dilutive line of credit from The Starwood Trust earlier this year, reinforcing confidence in Telomir’s strategy. The funding supports Telomir’s innovative pipeline, led by its breakthrough compound, Telomir-1, which has demonstrated preclinical efficacy in reversing age-related conditions, including Type 2 diabetes, by addressing root causes like oxidative stress and telomere shortening. Telomir is also advancing research in Alzheimer’s, cancer, osteoarthritis, and Wilson…

Continue Reading

WednesdayDec 11, 2024 2:02 pm

BioMedNewsBreaks — Astiva Health Eyes Continued Momentum on Heels of Remarkable Growth

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, anticipates strong growth in membership in 2025. The momentum is expected to build upon the record-setting performance already achieved this year in terms of network and membership expansion. “According to a company news release, membership is expected to grow by 70% or 7,000 members, a major increase from the numbers reported this year. Astiva Health started off with a membership jump in January 2024, when it reached 10,000 members (22% higher than the 3,100 members recorded in January 2023), and then again…

Continue Reading

WednesdayDec 11, 2024 8:45 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Secures Three-Year State Government Contract for Outfitter Satellite Connectivity Services

NextPlat (NASDAQ: NXPL, NXPLW)  announced that its U.S.-based connectivity division, Outfitter Satellite Inc., has been awarded a three-year contract by a U.S. state government to provide satellite connectivity services. The agreement includes satellite airtime service plans and hardware to support the government workforce during remote operations and natural disasters, with an option to extend for two additional years. Outfitter, acquired by NextPlat in April 2024, has over two decades of experience delivering satellite-based connectivity solutions and has generated significant recurring revenue from its services across North America. David Phipps, President of NextPlat, highlighted Outfitter’s role in driving domestic growth and its…

Continue Reading

TuesdayDec 10, 2024 2:40 pm

BioMedNewsBreaks — Adageis Engages IBN for Corporate Communications Expertise

  Adageis is a healthcare technology company dedicated to revolutionizing patient care through innovative value-based care solutions. Through integrating artificial intelligence (“AI”) and machine learning, Adageis’ Patented Risk Engine (“PRE”) transforms healthcare delivery, equipping providers with tools to enable value-based care, improve patient outcomes, and increase operational efficiency. The company’s flagship ProActive Care Platform integrates with existing electronic medical records (“EMR”) systems, offering a seamless, AI-powered solution. Adageis has selected IBN, a multifaceted financial news and publishing company for private and public entities, to spearhead its corporate communications efforts. As part of the client partner relationship, IBN will generate greater…

Continue Reading

TuesdayDec 10, 2024 1:40 pm

BioMedNewsBreaks – BioAdaptives Inc. (BDPT) Launches Xcellara(TM) — an Innovative Supplement That Harnesses Nature for Optimal Health

BioAdaptives (OTC: BDPT) today announced the launch of Xcellara(TM) Stem Cell Activator, a groundbreaking supplement that harnesses the extraordinary potential of stem cells' regeneration power through a blend of adaptogens, herbs and beneficial bacteria. The innovative formulation supports the body's natural repair mechanisms, promoting anti-aging and enhancing overall health and wellness. "This is an exciting milestone for BioAdaptives as we continue to push the boundaries of what's possible in natural health supplements," said the company’s CEO James Keener. "With the launch of Xcellara(TM) Stem Cell Activator, we're offering a product that's both innovative and deeply rooted in science, leveraging a…

Continue Reading

TuesdayDec 10, 2024 12:33 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Advances CNM-Au8 in ALS with FDA Guidance on Accelerated Approval Pathway

Clene (NASDAQ: CLNN) received FDA guidance on leveraging data from its ongoing expanded access programs (“EAPs”) to support an accelerated approval application for CNM-Au8, its treatment for ALS. The FDA recommended using neurofilament light chain (“NfL”) biomarker analyses to substantiate the drug’s efficacy. Clene plans to submit additional data in mid-2025, alongside commencing the Phase 3 RESTORE-ALS trial. Clinical findings presented at an FDA meeting highlighted CNM-Au8’s significant survival benefits and benign safety profile, underscoring its potential as a transformative ALS therapy. Clene remains committed to addressing the urgent unmet needs of ALS patients. To view the full press release, visit https://ibn.fm/xFrwd…

Continue Reading